Finasteride vs Spironolactone: Switching Between Them

How Each Drug Works Against Androgens

Finasteride and spironolactone both dampen androgen signaling, but they do so at different steps in the hormonal cascade. That distinction determines who benefits, who faces risk, and how a switch should be managed.

Finasteride is a competitive inhibitor of type II 5-alpha reductase, the enzyme that converts testosterone into dihydrotestosterone (DHT). At 1 mg daily, it lowers scalp and serum DHT concentrations by roughly 70% without meaningfully reducing total testosterone 1. The drug was originally developed at 5 mg for benign prostatic hyperplasia. The 1 mg dose earned FDA approval for male pattern hair loss in 1997. DHT is the primary androgen responsible for miniaturizing hair follicles in genetically susceptible individuals, so blocking its production slows or reverses that process in a majority of men.

Spironolactone takes a broader approach. It binds directly to androgen receptors, preventing testosterone and DHT from activating them. It also reduces adrenal androgen production and increases sex hormone-binding globulin (SHBG), which lowers free testosterone levels 2. Originally approved as a potassium-sparing diuretic for heart failure and hypertension, spironolactone has been used off-label in dermatology for decades. The Endocrine Society notes that anti-androgen therapy with spironolactone is a "reasonable option for women with androgen-dependent skin conditions who are not planning pregnancy" 3.

The clinical implication is straightforward. Finasteride targets one enzyme. Spironolactone blocks the receptor itself plus multiple upstream pathways. This makes spironolactone a wider-spectrum anti-androgen, but it also introduces more systemic effects, including diuresis, electrolyte shifts, and menstrual irregularities.

Who Is a Candidate for Each Drug

Patient selection diverges sharply along sex and diagnosis lines. The wrong choice carries real clinical consequences.

Finasteride at 1 mg daily is indicated for men with androgenetic alopecia (AGA). In the Kaufman et al. study, men receiving finasteride 1 mg for 5 years maintained increased hair counts on vertex scalp compared to baseline, while placebo-treated men continued to lose hair 1. Finasteride is contraindicated in pregnant women and women who may become pregnant because DHT suppression during fetal development can cause ambiguous genitalia in male fetuses. The FDA classifies it as pregnancy category X 4. Some clinicians do prescribe low-dose finasteride (2.5 to 5 mg) off-label to postmenopausal women with AGA, but this remains a minority practice.

Spironolactone is used almost exclusively in women. Doses between 100 and 200 mg daily have shown efficacy for female pattern hair loss, and the 50 to 200 mg range is the standard for hormonal acne in adult women 2. A retrospective study by Charny et al. found that 74.3% of women with AGA treated with spironolactone showed clinical improvement, with the best responses at doses of 200 mg/day 5. Spironolactone is not used in men for dermatologic conditions because its anti-androgen effects cause gynecomastia, breast tenderness, and sexual dysfunction at therapeutic doses.

The practical overlap is narrow. A postmenopausal woman with AGA who has tried spironolactone might be considered for finasteride if anti-androgen therapy has failed. A premenopausal woman would almost never receive finasteride. A man would almost never receive spironolactone for hair or skin.

Efficacy Data: What the Trials Show

No head-to-head randomized trial has compared finasteride and spironolactone directly. All comparisons are cross-trial, and the populations studied differ by sex, so direct efficacy rankings are unreliable.

For finasteride, the key data comes from two multicenter RCTs. In the Kaufman et al. trial, 1,553 men aged 18 to 41 with mild to moderate vertex hair loss received finasteride 1 mg or placebo for 5 years. At year 1, finasteride-treated men had a mean increase of 107 hairs in a 5.1 cm² target area compared to a loss of 20 hairs in the placebo group. At year 5, treated men still maintained a net increase above baseline while placebo men had continued decline 1. A separate trial by the Prostate Cancer Prevention Trial group showed that finasteride 5 mg reduced prostate cancer incidence by 24.8% over 7 years, confirming potent DHT suppression at higher doses 6.

For spironolactone, evidence is largely observational. The Layton et al. analysis examined adult women with persistent hormonal acne treated with spironolactone at doses of 50 to 200 mg/day and found consistent reductions in inflammatory lesion counts 2. A 2020 systematic review by Garrido-Colmenero et al. pooled data from 10 studies involving over 600 women with AGA and reported that spironolactone produced "moderate to significant improvement" in 50 to 74% of patients, though most studies were retrospective with small sample sizes 7.

Dr. Wilma Bergfeld, former president of the American Academy of Dermatology, has stated: "Spironolactone remains our most commonly prescribed systemic anti-androgen for female pattern hair loss in the United States, despite the absence of FDA approval for this indication" 8.

The evidence gap matters. Finasteride has level 1 evidence from large RCTs in men. Spironolactone has level 3 to 4 evidence from retrospective and open-label studies in women. Comparing their "efficacy" is comparing different evidence quality in different populations for partially overlapping but distinct conditions.

Side Effect Profiles and Monitoring

Each drug carries a distinct side effect burden that directly affects switching decisions.

Finasteride side effects center on sexual function. In the Kaufman et al. trial, 3.8% of finasteride-treated men reported decreased libido compared to 2.1% on placebo. Erectile dysfunction occurred in 1.3% versus 0.7% 1. These effects typically resolved after discontinuation. A small subset of patients report persistent sexual, neurological, or psychological symptoms after stopping finasteride, a condition sometimes termed "post-finasteride syndrome." The FDA added warnings about depression and suicidal ideation to the finasteride label in 2012 4. Routine lab monitoring is not required for finasteride at 1 mg, though some clinicians check baseline PSA in men over 40 before starting therapy because finasteride reduces PSA by approximately 50%.

Spironolactone side effects reflect its diuretic and anti-androgen pharmacology. Hyperkalemia is the primary safety concern, particularly in patients with renal impairment or those taking ACE inhibitors, ARBs, or potassium supplements. A 2015 study by Plovanich et al. in JAMA Dermatology found that healthy young women taking spironolactone for acne had a hyperkalemia rate of only 0.72%, comparable to controls, questioning the necessity of routine potassium monitoring in this low-risk group 9. Menstrual irregularity occurs in 10 to 30% of premenopausal women. Breast tenderness affects approximately 5 to 10%. The American Academy of Dermatology guidelines recommend checking potassium and creatinine at baseline and at 4 to 8 weeks after initiation, then annually 10.

The monitoring burden differs substantially. Spironolactone requires lab work. Finasteride typically does not.

When and Why to Consider Switching

A switch between these two drugs is uncommon because they serve different populations, but specific clinical scenarios make it reasonable.

Women moving from spironolactone to finasteride. A postmenopausal woman who has not responded to spironolactone 200 mg/day after 12 months, or who develops intolerable side effects such as severe orthostatic hypotension or persistent hyperkalemia, may be a candidate for off-label finasteride. Because she is no longer of childbearing potential, the pregnancy contraindication is removed. Doses of 1 to 5 mg daily have been used in small case series 11. Before switching, confirm menopause by history or FSH levels. A washout period of 2 to 4 weeks after stopping spironolactone is reasonable to allow potassium levels to normalize and blood pressure to stabilize.

Women moving from finasteride to spironolactone. This is less common but could occur if a postmenopausal woman tried finasteride without adequate response. Spironolactone's broader anti-androgen mechanism may provide benefit through androgen receptor blockade where DHT reduction alone failed. Starting spironolactone at 50 mg daily and titrating up while tapering finasteride over 4 weeks avoids a gap in anti-androgen coverage.

Switching driven by side effects, not efficacy failure. A patient tolerating one drug's efficacy but not its side effects is the clearest switching indication. A woman experiencing severe diuresis and electrolyte issues on spironolactone may prefer the simpler side effect profile of finasteride. Conversely, a patient experiencing mood changes on finasteride might tolerate spironolactone well.

Dr. Jerry Shapiro, professor of dermatology at NYU Langone, has noted: "The decision to switch anti-androgens in female pattern hair loss should be guided by documented treatment failure at adequate doses for adequate duration, typically 12 months minimum" 12.

A Step-by-Step Switching Protocol

No published guideline addresses switching between finasteride and spironolactone specifically. The protocol below reflects standard anti-androgen transition practices used in dermatology clinics.

Step 1: Confirm adequate trial duration. Both drugs require a minimum of 6 months and ideally 12 months before efficacy can be assessed. A switch before 6 months is premature except for safety reasons 8.

Step 2: Document the reason for switching. Record whether the switch is for efficacy failure, side effect intolerance, or a change in reproductive status (for example, a woman entering menopause and becoming eligible for finasteride).

Step 3: Baseline labs before starting the new drug. If transitioning to spironolactone, check serum potassium, creatinine, and blood pressure. If transitioning to finasteride, no labs are strictly required, but a baseline liver panel is reasonable.

Step 4: Choose cross-taper or washout. For most patients, a 4-week cross-taper is preferred. Start the new drug at half the target dose while reducing the outgoing drug by 50%. After 2 weeks, bring the new drug to full dose and discontinue the old drug. A full washout (stopping one drug completely, waiting 4 to 6 weeks, then starting the other) is safer if there is concern about combined anti-androgen load or side effect overlap.

Step 5: Follow-up monitoring. Reassess clinically at 3 months and 6 months after completing the switch. For spironolactone, recheck potassium at 4 to 8 weeks 10. For finasteride, ask about mood and sexual function at each visit.

Step 6: Set outcome expectations. Inform the patient that any improvement from the prior drug may partially reverse during the transition period. Temporary increased shedding during a switch is normal and does not indicate treatment failure.

Combining Finasteride and Spironolactone

Combination therapy is rarely used because both drugs reduce androgen activity and their concurrent use may amplify side effects without proportionally increasing benefit. There are no published trials evaluating finasteride plus spironolactone together.

In theory, the combination could be additive: finasteride blocks DHT production while spironolactone blocks the androgen receptor, covering two different points in the pathway. Some clinicians have used low-dose combinations (finasteride 1 mg plus spironolactone 50 mg) in postmenopausal women with severe, refractory AGA 11. The risk profile is not well characterized for this combination.

The more common pairing in clinical practice is either drug combined with topical minoxidil. Minoxidil works through a vasodilatory, androgen-independent mechanism, making it complementary rather than redundant. A 2019 review in the Journal of the American Academy of Dermatology recommended combination therapy with minoxidil as the preferred escalation strategy before switching between systemic anti-androgens 8.

If you are on one anti-androgen and not seeing results, adding minoxidil 5% topical once daily is a lower-risk next step than switching to or adding a second anti-androgen.

Acne-Specific Considerations

While this comparison focuses primarily on hair loss, acne drives many prescribing decisions, particularly for spironolactone in women.

Spironolactone is one of the most commonly prescribed systemic treatments for adult female hormonal acne. The Layton et al. analysis confirmed efficacy across the 50 to 200 mg/day range, with most patients responding at 100 mg daily 2. Acne along the jawline, chin, and lower cheeks in women over 25 is the classic phenotype that responds to anti-androgen therapy. A large retrospective cohort study in the BMJ found that spironolactone and oral antibiotics had comparable long-term acne outcomes, with spironolactone showing fewer antibiotic resistance concerns 13.

Finasteride has minimal evidence for acne treatment. Because it blocks only type II 5-alpha reductase (found predominantly in hair follicles and prostate), it does not substantially reduce the sebum production driven by androgen receptor activation in sebaceous glands. A woman switching from spironolactone to finasteride for hair loss who also has hormonal acne should expect her acne to potentially worsen, because finasteride does not replicate spironolactone's broad anti-androgen effect on sebaceous glands.

This is a common oversight. If a patient's treatment goals include both hair and skin, spironolactone addresses both. Finasteride addresses only hair.

Cost and Access Comparison

Generic finasteride 1 mg costs approximately $4 to $15 per month at most U.S. pharmacies. It is available by prescription only and is not typically covered by insurance for cosmetic hair loss indications, though GoodRx-type discount programs bring the out-of-pocket cost below $10 for most patients.

Generic spironolactone 100 mg costs approximately $4 to $20 per month. Insurance coverage is more likely because spironolactone has FDA-approved cardiovascular indications, and the prescription can be written for an approved use even when the clinical intent is dermatologic. Both drugs are inexpensive generics. Cost is rarely the deciding factor in choosing between them.

Neither drug requires specialty pharmacy dispensing or prior authorization in most cases. Both are oral tablets taken once daily. The main access barrier is finding a prescriber comfortable with off-label use, particularly for finasteride in postmenopausal women or spironolactone at dermatologic doses of 100 to 200 mg in younger women who need concurrent contraception.

Reproductive Safety and Contraception Requirements

Reproductive safety is the single most important variable separating these drugs in clinical practice.

Finasteride is FDA pregnancy category X. Exposure during pregnancy can cause hypospadias and ambiguous genitalia in male fetuses. Women of childbearing potential should not handle crushed or broken finasteride tablets 4. When prescribed off-label to premenopausal women (rare, and only by specialists), two forms of contraception are required, and a pregnancy test should be confirmed negative before initiation.

Spironolactone carries FDA pregnancy category C designation (animal studies showed feminization of male fetuses at high doses). The American Academy of Dermatology recommends reliable contraception for all premenopausal women taking spironolactone for acne or hair loss 10. Combined oral contraceptive pills are frequently co-prescribed because they provide contraception, additional anti-androgen benefit through SHBG elevation, and regularization of menses disrupted by spironolactone.

A woman planning pregnancy should discontinue either drug. Finasteride has a half-life of approximately 6 hours, and DHT levels normalize within 2 weeks of cessation. Spironolactone's anti-androgen effects resolve within 2 to 3 days of discontinuation given its short half-life (1.4 hours for the parent compound). A 1-month washout before attempting conception is a standard clinical recommendation for both drugs 3.